Global Protein Engineering Industry Forecast 2019 by Key Companies & Competition

Protein Engineering Market [Products (Monoclonal Antibody, Insulin
Analog, Modified EPO), Technology (Sequential Modification,
Glycosylation, PEGylation), and Applications (Therapeutics, Diagnostics,
Research)] - Global Forecast to 2017
By
MarketsandMarkets
Published: March 2014
No. of Pages: 148
Single User License: US$ 4650
Corporate User License: US$ 7150
Order this report by calling
+1 888 391 5441 or Send an email
to sales@reportsandreports.com
with your contact details and
questions if any.
© ReportsnReports.com / Contact sales@reportsandreports.com 1

Protein Engineering Market Products, Technology and
Applications - Global Forecast to 2017
New Market Research Report on “Protein Engineering Market [Products (Monoclonal
Antibody, Insulin Analog, Modified EPO), Technology (Sequential Modification,
Glycosylation, PEGylation), and Applications (Therapeutics, Diagnostics, Research)] -
Global Forecast to 2017” added to ReportsnReports.com.
Proteins exhibit high specificity and less immunogenicity and are widely used as
therapeutic agents in the treatment of various disorders and diseases. There are
more than 200 protein-based products currently being marketed; 90% of them are
used as therapeutics. In order to improve their clinical potential, second generation
recombinants are being developed, each exhibiting improved efficiency and potency
depending on their applications.
The global Protein Engineering Technologies Market (2012-2017) report analyses the
market by technology, products, applications, and geography. It also includes recent
technology trends, patents, and funding analysis. In addition, it also covers factors
driving and restraining the growth of the market and market scenario in the U.S.,
Europe, Asia, and Rest of the World (RoW)..
Order this report by calling +1 888 391 5441 or Send an email to
sales@reportsandreports.com with your contact details and questions if any.

The protein engineering market is driven by the need for drugs with improved efficiency
and specificity, technological capabilities, rise of antibody based drugs, and steady growth
in the therapeutic market. With growing incidences of cancer, autoimmune disorders, and
infectious disease, spurt of new opportunities for growth of the market is expected by the
end of this decade. However, development costs, stringent regulatory issues, and risk of
failure of the drug in the testing phase restraints the growth of the market. Further, the
availability of generics and patent infringements is posing a threat to the market.
Complete report available @ http://www.reportsnreports.com/reports/231673-protein-engineering-
market-products-monoclonal-antibody-insulin-analog-modified-epo-technology-
sequential-modification-glycosylation-pegylation-and-applications-therapeutics-
diagnostics-research-global-forecast-to-2017.html .

The global protein engineering market is expected to grow at a CAGR of 10.9%; this growth is
majorly fuelled by monoclonal antibodies, which is the fastest growing segment in
therapeutics. The use of monoclonal antibodies in therapeutics such as oncology, auto immune
and inflammatory diseases are expected to increase during the forecast period. Chinas growing
interest in research of monoclonal antibodies is expected to increase market share further. The
market is likely to face competition from the entry of generics; however, with many therapeutic
proteins in the pipeline, the market is expected to grow exponentially. Insulin analogs, which
are more efficient than the recombinant insulin, are also a contributing factor for growth of the
market. Diagnostics is another segment in focus; monoclonal antibodies are being used
extensively in diagnostics and in assays for research.
The report also profiles leading participants of the industry with their recent developments and
other strategic industry activities. These include Genentech (U.S.), Amgen (U.S.), Roche
(Switzerland), Eli Lilly (U.S.), Novartis (Switzerland), GlaxoSmithKline (U.K.), Bristol-Myers
Squibb (U.S.), Johnson & Johnson (U.S.), Merck (U.S.), Pfizer (U.S.), Sanofi (France), Affymax
(U.S.), Biogen Idec, (U.S.), Medimmune (U.S.) Affimed (Germany), and Obodies (New Zealand).

Table of Contents
1 Introduction(Slide No. 18 - 23)
2 Executive Summary (Slide No. 24 - 27)
3 Protein Engineering Technologies – Landscape
Analysis (Slide No. 28 - 45)
4 Applications (Slide No. 46 - 54)
5 Market Landscape Analysis(Slide No. 55 - 92)
6 Geographic Analysis (Slide No. 93 - 100)
7 Technology And Product Portfolio (Slide No. 101
- 105)
8 Competitive Landscape (Slide No. 106 - 111)
9 Analyst Insights And Recommendation (Slide
No. 112 - 114)
10 Company Profiles (Slide No. 115 - 146)
10.1 Genentech, Inc.
10.2 Amgen, Inc.
10.3 Biogen Idec, Inc.
10.4 Novartis Ag
10.5 Glaxo Smithkline Plc
10.6 Eli Lilly & Co
10.7 Bristol Myers Squibb Co.
10.8 Johnson & Johnson
10.9 Merck & Co., Inc.
10.10 Sanofi
10.11 Pfizer, Inc.
10.12 Regeneron Pharmaceuticals, Inc.
10.13 Eleven Biotherapeutics
10.14 Toolgen, Inc. (Korea)
10.15 Dna2.0, Inc. (U.S.)
Inquire for discount on this report @
http://www.reportsnreports.com/contacts/Discount.aspx?name=231673 .

ReportsnReports.com is your single source for all market research needs. Our database
includes 350,000+ syndicated market research reports from 100+ leading global
publishers covering in-depth analysis of over 5000 micro markets. With comprehensive
information about the publishers and their report methodology, data sources, etc. we
help you in your purchase decision by mapping your information needs with the most
relevant available reports in our library. Join us on social platforms to keep yourself
updated about the latest market intelligence for industry of your interest.

Global Protein Engineering Industry Forecast 2019 by Key Companies & Competition

Recommended

Recommended

More Related Content

Recently uploaded

Recently uploaded (20)

Featured

Featured (20)

Global Protein Engineering Industry Forecast 2019 by Key Companies & Competition